Boston, MANCT07572383Now EnrollingIRB Ready

Interstitial Lung Disease Clinical Trial in Boston, MA

Access cutting-edge interstitial lung disease treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Peter Caravan

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access interstitial lung disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related interstitial lung disease treatment provided free

Apply for This Boston Location

Check if you qualify for this interstitial lung disease clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Interstitial Lung Disease Study in Boston

The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).

Sponsor: Peter Caravan

Who Can Participate

Inclusion Criteria

Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.
Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and / or prednisone for clinically indicated non-IPF ILD treatment.
Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1.
Forced vital capacity (FVC) of \>/= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) \>/= 25% predicted on PFTs performed at Visit 1.

Exclusion Criteria

Current or prior exposure to FDA approved anti-fibrotic therapy.
Extent of emphysema greater than extent of fibrosis.
Pregnancy or plans to become pregnant at baseline or during follow-up.
Contraindications to MRI.
Contraindications to receiving gadolinium-based contrast agents.
Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year.
Estimated glomerular filtration rate (eGFR) \< 30 mL/min (only for individuals with a history of chronic kidney disease).
Clinically significant pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy.
Respiratory infection within the prior 6 weeks.
Smoking of any kind within the prior 6 months.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07572383) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Interstitial Lung Disease Treatment Options in Boston, MA

If you're searching for interstitial lung disease treatment options in Boston, MA, this clinical trial (NCT07572383) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced interstitial lung disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all interstitial lung disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Boston, MA

See all ankylosing spondylitis clinical trials recruiting in Boston — not just this study.

Browse Ankylosing Spondylitis Trials in Boston →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsCOPD TrialsPulmonary Fibrosis TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA